ASSESSING METASTASIS/RELAPSE IN SENTINEL LYMPH NODE DISSECTION MELANOMA PATIENTS

该计划项目的重点是评估 高危 AJCC II 期患者的前哨淋巴结清扫术 (SLND) 参加了多中心试验（MSLT）。准确识别和 前哨淋巴结分析可以改善疾病分期并指导 进一步治疗。然而，需要更好的方法来检测 早期患者的转移性疾病和复发预测。的 接受 SLND 的患者的黑色素瘤病灶、前哨淋巴结和血液 是评估新分子方法学的宝贵资源。 该项目将重点开发新的分子方法来改善 检测血液和前哨淋巴结中的转移性疾病。 为 RT-PCR 和自动 Souther 印迹分析开发的黑色素瘤标记物 将用于评估血液和前哨淋巴结。我们将评估 这些分子标记在检测中的临床应用 使用来自以下组织的血液样本进行亚临床疾病和复发预测 SLND 患者。我们还将使用黑色素瘤标记物 RT-PCR 来检测 前哨淋巴结冷冻和存档石蜡选择中的转移 节点。主要目标是改善微转移的检测 前哨淋巴结疾病。主要目标是改善 前哨淋巴结微转移病灶和复发病灶的检测 血液中的亚临床疾病以确定其潜力 临床病理学在疾病分期和预后中的应用。一个方法有 被开发用于评估血清中的肿瘤特异性 DNA 标记。这些 标记物将使用前瞻性评估作为肿瘤进展指标 和档案血清。目标是识别患有高 发展侵袭性疾病的可能性。 MSLT 档案和 前瞻性样本及其临床随访提供了独特的 验证和确定这些新分子的临床效用的资源 接近。

The Program Project's focus os on the assessment of the efficacy of sentinel lymph node dissection (SLND) in high-risk AJCC Stage II patients enrolled in the multi-center trial (MSLT). Accurate identification and analysis of the sentinel node can improve disease staging and guide further treatment. However, better methods are needed for the detection of metastatic disease and prediction of relapse in early-stage patients. The melanoma lesion, sentinel lymph node and blood of patients undergoing SLND are valuable resource for assessing new molecular methodologies. The project will focus on developing new molecular approaches to improve detection of metastatic disease in blood and sentinel lymph nodes. Melanoma markers developed for RT-PCR and automated Souther blot analysis will be used to evaluate blood and sentinel lymph nodes. We will assess the clinical utility of these molecular markers for detection of subclinical disease and prediction of relapse using blood specimens from SLND patients. We will also use melanoma marker RT-PCR to detect metastasis in frozen and archival paraffin selection of sentinel lymph nodes. The main objective will be to improve detection of micrometastic disease in sentinel lymph nodes. The main objective will be to improve detection of micrometastatic disease in sentinel lymph nodes and recurrent subclinical disease in blood to determine their potential clinicopathological utility in disease staging and prognosis. A method has been developed to asses tumor- specific DNA markers in serum. These markers will be assessed as tumor progression indicators using prospective and archival serum. The objective will be to identify patients with high potential for developing aggressive disease. The MSLT archival and prospective specimens along with their clinical follow up provide a unique resource to validate and determine clinical utility of these new molecular approaches.